Argos Therapeutics Inc (NASDAQ:ARGS) Stock Rises on Announcement

Argos Therapeutics Inc (NASDAQ:ARGS)

Shares of Argos Therapeutics Inc (NASDAQ:ARGS) rallied 12.65% after the company confirmed the dosing of the first HIV patient with AGS-004 dendritic cell therapy. The Phase 2 HIV eradication trial is being conducted in partnership with the University of North Carolina.

ARGS Stock Performance

The patient dosing marks the first time that an HIV patient has received a therapy utilizing RNA antigens from his latent lateral reservoir. The news did little to reverse the direction of ARGS stock as it continues to languish around all-time lows.

The stock is currently trading in a tight $0.21 – $0.25 per share range. Argos Therapeutics Inc (NASDAQ:ARGS) has underperformed the overall industry having shed more than 80% in market value since the start of the year. It awaits to be seen if the HIV trial is the catalyst that will help push the stock up from the current trading levels.

Argos Therapeutics Inc (NASDAQ:ARGS)
One month ARGS stock price chart

HIV Trial

The use of the RNA antigens from the patient’s latent reservoir was prompted by the fact the latent reservoir is where the HIV virus is most dominant, hidden from attack by the immune system. Current treatments agents have struggled to target the HIV virus in the reservoir rendering them inefficient.

The ongoing trial seeks to test whether boosting antiviral immunity with AGS-004, known to stimulate T-cells that attack HIV infected cells, will help expose the virus to the immune system to facilitate their eradication. According to Argos Therapeutics Inc. (NASDAQ:ARGS), the isolation of specific viral antigens from patients own could enable more focused immune system attack on the HIV virus.

“We believe that the new manufacturing process may allow AGS-004 to generate immune responses that are much better matched to the viral variants that will emerge during latency reversal with vorinostat treatment and, therefore, maximize the opportunity for viral clearance,” said Charles Nicolette, Chief Scientific Officer of Argos.

Argos Therapeutics Inc (NASDAQ:ARGS) has already enrolled four patients who will receive the AGS-004 manufactured using RNA antigens derived from infectious plasma. Results from ongoing Phase 2 eradication trial continues to be well tolerated.

Argos Therapeutics Inc (NASDAQ:ARGS) is funding the AGS-004 trial with finances provided by the National Institute of Health and the National Institute of Allergy and Infectious Diseases as well as Collaboratory of Research for Aids Eradication.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $ARGS and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

Verastem Inc (NASDAQ:VSTM) Blood Cancer Drug Meets Primary Endpoints

Verastem Inc (NASDAQ:VSTM)

Shares of Verastem Inc (NASDAQ:VSTM) rallied 28.13% after the company announced positive Phase 3 trial results for its blood cancer drug. The stock had initially jumped 50.3% after the company announced that Duvelisb met its primary endpoints in the late stage trial.

Duvelisib is an oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma under trial for the treatment of hematologic cancers such as indolent non-Hodgkin lymphoma (iNHL) and other T cell lymphomas. Verastem Inc (NASDAQ:VSTM) tested the drug on 319 patients suffering from chronic lympocytic leukemia or small lymphocytic lymphoma

In addition to the positive Phase 2 trial results, the drug is also supported by compelling Phase 1 results that demonstrated a 50% investigator-assessed response rate.

VSTM Investor Reaction

The positive clinical trial results saw the stock gap higher to highs of $5.50 a share before retreating to end the day at $4.92 a share. The stock has already broken key resistance levels of $4.00 and $4.50 a share, further affirming a bullish run that began in July. Verastem Inc (NASDAQ:VSTM) shares are already up by more than 300% for the year.

Verastem Inc. (NASDAQ:VSTM) is currently trading near all-time highs. Renewed investor interest on the stock comes on the biopharmaceutical company saying that Duvelisib reduced the risk of disease progression or death by 48%, compared to standard care Arzerra.

Fuelling investor interests are reports that the Duvelisib, if approved, could generate as much as $400 million in sales for the company. Equity firms have already taken note of Duvelisib potential, with analysts at Oppenheimer initiating coverage of the stock with a ‘buy’ rating.

One month VSTM stock price chart

Regulatory Push

Verastem Inc (NASDAQ:VSTM) plans to share the clinical data with the U.S Food and Drug Administration (FDA) with the goal of filling a New Drug Application (NDA). The filling is to be supported by results from DUO study and CLL/SLL and the DYNAMO study – all of which achieved primary endpoints. The company has also confirmed plans to file for a marketing application for the drug.

Verastem Inc (NASDAQ:VSTM) is also planning to expand Duvelisb development program with a view of carrying out trials on its ability to treat Peripheral T-Cell Lymphoma. Duvelisib has already been granted Fast Track Designation by the FDA for the treatment of PTCL.

“Expansion of the Duvelisib clinical development program, and the accompanying receipt of Fast Track designation from the FDA are important steps in Verastem’s strategy to efficiently develop the potential of duvelisib in additional cancers such as T-cell malignancies,” said Robert Forrester, President and Chief Executive Officer of Verastem Inc (NASDAQ:VSTM).

Board Appointment

Following the positive Duvelisib trial results, Verastem Inc. (NASDAQ:VSTM) has confirmed the appointment of Brian Stuglik to the board of directors. He joins the company with over 30 years’ experience in Pharmaceutical and oncology commercialization.

“Brian Stuglik is an accomplished executive with significant oncology commercialization expertise who can bring immediate value to Verastem as we now move towards commercializing duvelisib,” said Mr. Forrester.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $VSTM and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

Delcath Systems, Inc. (NASDAQ:DCTH) Turns To Reverse Stock Split

Delcath Systems, Inc. (NASDAQ:DCTH)

Delcath Systems, Inc. (NASDAQ:DCTH) poor run in the market continued after the Chief Executive Officer, Jennifer K. Simpson, issued a letter to stockholders. The stock continues to trade at all-time lows and the company has been hit with a delisting notice by the NASDAQ capital markets.

Stock Performance

Shares of Delcath Systems, Inc. (NASDAQ:DCTH) continue to trade in a downtrend in a tight $0.10 – $0.11 trading range. The strength of the sell-off wave threatens to push the stock to its 52-week lows having dropped from highs of $3 a share in late 2016. In a bid to shore up the stock price, the company has proposed a reverse stock split that it hopes shareholders will approve at an upcoming AGM.

Delcath Systems, Inc. (NASDAQ:DCTH)
One month DCTH stock price chart

Reverse Stock Split Push

According to Simpson, approval of the proposed reverse stock-split will result in the extinguishment of a Note with a majority note holder. The transaction should also adjust the floor price of the remaining note with a minority note holder.

Delcath Systems, Inc. (NASDAQ:DCTH) is also banking on the reverse stock-split to solve the minimum bid requirement for the NASDAQ. Regaining compliance is crucial as listing in the exchange allows the company to gain access to a wide range of capital opportunities.

“Should the Company not obtain approval for a reverse stock split, it is likely that the Company will be delisted from NASDAQ. We believe remaining on the NASDAQ provides liquidity and other benefits to the Company and its investors,” Delcath Systems, Inc. (NASDAQ:DCTH) in a statement.

Delcath Systems, Inc. (NASDAQ:DCTH) has also reached an agreement with a majority Note holder of Convertible notes through which 90% of the outstanding debt is to be extinguished upon the approval of the reverse stock-split . The transaction should mitigate potential future dilution of the stock-split.

In addition to reducing the amounts of outstanding shares, the reverse stock-split should provide Delcath Systems, Inc. (NASDAQ:DCTH) with the flexibility to raise equity capital. The company hopes to raise money to fund its clinical development programs as well as finance its commercial efforts in Europe.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $DCTH and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

Synergy Pharmaceuticals Inc. (NASDAQ:SGYP): Did Investors Overreact?

Synergy Pharmaceuticals Inc. (NASDAQ:SGYP)

Shares of Synergy Pharmaceuticals Inc (NASDAQ:SGYP) shed 3.65% in market value after the company announced a new $300 million debt financing. The biopharmaceutical company secured the new financing from CRG LP, a healthcare focused investment firm.

Synergy Pharmaceutical Sell Off

Tuesday’s sell-off continued a trend that has plagued the stock for the better part of the year. Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) is currently trading at the lower end of its $2.89 – $3.25 trading range, and appears to be closing on its 52-week low of $2.85 a share.

Synergy Pharmaceuticals Inc. (NASDAQ:SGYP)
One month SGYP stock price chart

Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) has underperformed the overall industry even though it has released positive news. Early this year the company won an FDA approval for the use of its drug, Trulance for the treatment of idiopathic constipation. The condition affects about 35 million people in the U.S.

Investors were confident that Trulance would reinvigorate Synergy Pharmaceutical prospects given that a rival drug marketed by Allergan (NYSE:AGN) and Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) generated sales of $625 million last year. That has not been the case, as the stock has continued to hit lower lows in the market.

Trulance is still seen by analysts as a major catalyst that could make or break Synergy Pharmaceuticals Inc. (NASDAQ:SGYP). The drug boasts clinical advantages that could make it as popular than Linzess, its primary competitor. In clinical trials, the drug reported lower diarrhea, abdominal pain, and flatulence when compared to Linzess.

Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) is currently working on expanding the labeling of the drug, a move that it hopes will make it popular thus attract more sales. The company has also made a submission to the FDA to have the drug approved for the treatment of irritable bowel syndrome. A decision on the same is expected early next year.

$300 Million Debt Financing

In addition to positive news on the drug development front, the $300 million debt financing could have a significant impact on the company’s prospects going forward.

“This non-dilutive financing enhances our cash position and provides us with financial flexibility to continue to execute on the launch of TRULANCE and achieve our business objectives, which we are confident will ultimately maximize long-term shareholder value,” said Gary Gemignani, Chief Financial Officer

CRG agreeing to lend Synergy Pharmaceuticals Inc (NASDAQ:SGYP) $300 million underscores its confidence in the company’s long term prospects.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $SGYP and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

FuelCell Energy Inc (NASDAQ:FCEL) Preferred Stock Pricing Rattles Investors

FuelCell Energy Inc (NASDAQ:FCEL)

FuelCell Energy Inc (NASDAQ:FCEL) slumped 3.75% after announcing the pricing of a $33.5 million convertible preferred stock transaction. Investors sent the stock lower even after the company announced a new 20 megawatt fuel cell project in South Korea.

FuelCell Stock Performance

The sell-off is already arousing concerns as to whether it will mark the end of a bullish run that began in May. FuelCell Energy Inc (NASDAQ:FCEL) is currently trading in a $1.45 – $1.63 trading range with a 52-week low of $0.80 a share.

FuelCell Energy Inc. (NASDAQ:FCEL) has struggled to rise above the $1.55 mark which acts as a key resistance level. The stock closing above the $1.63 could fuel a run to the $2.00 a share mark, which appears to be another resistance level.

FuelCell Energy Inc (NASDAQ:FCEL)
One month stock price chart for FCEL.

However, investor’s sentiments on the stock is waning after the pricing of the new stock offering. A point of concern is that the offering could plummet the company into more debt.

FuelCell Energy Inc (NASDAQ:FCEL) plans to offer 33,500 shares of convertible stock with a stated face value of $1,000 a share. The shares carry a 0.0% dividend and can be converted into common shares at $1.84 per common share. Each preferred share is being sold at $895.52 for gross proceeds of $30.0 million.

The company plans to use net proceeds from the offering for working capital purposes as well as financing of a number projects already underway. The offering should close on or about September 8, 2017.

20 Megawatt Fuel Cell Project

Part of the funds from the proposed offering are to be used to finance 20-megawatt fuel cell project that FuelCell Energy Inc (NASDAQ:FCEL) is working on, in conjunction with Korea Southern Power Company. Works on the project should begin before the end of the year with the facility poised to be fully operational next year.

The SureSource 3000 power plant is to produce clean electricity and thermal energy for use in district heating systems. Hanyang Industrial Development Company is to provide the engineering procurement and construction services for the project.

“This is the first fuel cell project for KOSPO and we are pleased that the value proposition of our SureSource solutions meets the exacting needs of KOSPO, one of Korea’s largest utilities. Our multi megawatt, scalable easy-to-site clean energy solutions are well-suited for utility-scale applications such as this project,” said FuelCell Energy Inc (NASDAQ:FCEL) CEO, Chip Bottone.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $FCEL and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms

Pulmatrix Inc (NASDAQ:PULM) Stock Explodes On New Grant

Pulmatrix Inc (NASDAQ:PULM)

Pulmatrix Inc (NASDAQ:PULM) stock gained 39.55% after the company announced it had received an award from the Cystic Fibrosis Foundation. The award is for the development of the company’s lead antifungal product PUR100, a novel treatment for allergic bronchopulmonary aspergillosis (ABPA).

Pulmatrix Inc (NASDAQ:PULM)
One month stock price chart for PULM

Pulmatrix Stock

The grant helped push Pulmatrix Inc (NASDAQ:PULM) up the charts after having come under immense selling pressure in the recent past. Since February, the stock has underperformed the overall market having slid from highs of $7 a share to lows of $1.60 a share.

Wednesday’s rally helped push the stock above a key resistance level awaiting to see if the momentum is strong enough to push it to the $3 a share mark. The new funding appears to have reinvigorated investor’s sentiments on the stock as it is poised to further strengthen the company’s pipeline of drugs.

“This award will help fund the nonclinical safety studies needed for the Phase 1/1B clinical trial that we plan to begin in 2018. It underscores the potential for PUR1900 to treat this serious condition, which is currently a major unmet medical need,” said CEO, Dr. Robert Clarke.

Pulmatrix Pipeline

PUR1900 has already received an Orphan Drug designation and a Qualified Infectious Disease Product designation from the U.S. Food and Drug Administration (FDA) for the treatment of fungal infections. The two designations provide Pulmatrix Inc (NASDAQ:PULM) with up to 12 years of market exclusivity should the drug gain regulatory approval.

In addition to PUR1900, Pulmatrix Inc (NASDAQ:PULM) is also working on PUR1800, a novel treatment for acute exacerbations of Chronic Obstructive Pulmonary Disease (COPD). The candidate drug has already been tested in a multi dose proof-of principle trial in COPD patients.

Q2 Financial Report

Separately, Pulmatrix Inc (NASDAQ:PULM) stock reported a net loss of (-$5.6) million for the second quarter – down from a net loss of (-$9.2) million reported last year. The decrease was primarily due to a non-recurrence of 2016 write-off charges. The company did not generate any revenue in the quarter compared to $0.3 million reported last year. That is mainly due to the conclusion of a clinical study for the development of PUR0200.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $PULM and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.